NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
PBH
Prestige Consumer Healthcare Inc.
PBH has a slight edge over NVO overall, supported by stronger valuation and lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PBH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
PBH's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PBH in the historical PE scenario, which offers more potential upside but is not a forecast.
PBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.5x | $45.32 | — |
| Cheap | 13x | $41.99 | -7.4% |
| Current | 14x | $45.32 | — |
| Fair | 15x | $48.52 | +7.1% |
| Expensive | 18x | $57.31 | +26% |
Historical ranges are pointers, not guarantees.
PBH's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
PBH has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PBH on earnings, with more consistent year-over-year improvement.
PBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.78 | +48% |
| Q3 2026 | $3.24 | -20% |
| Q2 2026 | $3.57 | -16% |
| Q1 2026 | $3.91 | -8.9% |
| Q4 2025 | $3.78 | -11% |
| Q3 2025 | $4.03 | -1.9% |
| Q2 2025 | $4.26 | +4.2% |
| Q1 2025 | $4.29 | +2.9% |
| Q4 2024 | $4.27 | +$5.88 |
PBH earned $3.24 per share over the past year, down 20% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PBH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PBH on profitability, with a higher operating margin.
PBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $336.3M | +23% |
| Q2 2026 | $265.7M | +6.5% |
| Q1 2026 | $281.6M | -5% |
| Q4 2025 | $283.4M | -2.4% |
| Q3 2025 | $274.1M | -3.4% |
| Q2 2025 | $249.5M | -6.6% |
| Q1 2025 | $296.5M | +7% |
| Q4 2024 | $290.3M | +2.7% |
PBH's revenue has picked up after four years of holding roughly level: $336M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.1 points |
| Q2 2026 | 20% | -9 points |
| Q1 2026 | 27% | -3 points |
| Q4 2025 | 29% | -2.6 points |
| Q3 2025 | 29% | -0.7 points |
| Q2 2025 | 29% | +1.8 points |
| Q1 2025 | 30% | +0.2 points |
| Q4 2024 | 32% | +1 points |
PBH's operating margin was 24% last quarter, down 5.1 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PBH on cash flow, with more consistent year-over-year improvement.
PBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.2M | -38% |
| Q2 2026 | $67.1M | -14% |
| Q1 2026 | $37.6M | -36% |
| Q4 2025 | $75.3M | +18% |
| Q3 2025 | $55.4M | -18% |
| Q2 2025 | $78.2M | +46% |
| Q1 2025 | $58.4M | -8.5% |
| Q4 2024 | $63.5M | -8.6% |
PBH's free cash flow has been positive every quarter for seven years: $214M over the past year, down 16% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11K shares |
| 1 year | -3.4% | -1.7M shares |
| 3 years | -5% | -2.5M shares |
| 5 years | -6.3% | -3.2M shares |
| Available history | -6.4% | -3.2M shares |
PBH has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $690,000 |
| Q4 2025 | $45.8M |
| Q3 2025 | $75M |
| Q2 2025 | $34.8M |
| Q1 2025 | $11.3M |
| Q4 2024 | $2.4M |
PBH spent $47M buying back its own shares over the past year, down 62% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over PBH on leverage, with a lower net debt burden relative to earnings.
PBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 2.6x | Moderate |
PBH's net debt is about 6.2 years of its operating earnings (EBITDA), up from 2.4 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 25.2 | Neutral |
PBH's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PBH on valuation relative to its sector.
PBH PE vs Healthcare Sector
| Metric | PBH | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 46% below |
| PE % | 29 | 29 | Same percentile |
PBH is trading at 14x earnings, a 46% discount to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over PBH on trend strength, trading above more of its moving averages.
PBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 3.4% below |
| 20 week MA | $48.9 | 7.3% below |
| 50 week MA | $54.7 | 17% below |
| 100 week MA | $65.0 | 30% below |
| 200 week MA | $65.3 | 31% below |
PBH is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PBH on returns for 2026, with the stronger performance.
PBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $34.9 | -14% |
| 2021 | $34.9 | $61.9 | +77% |
| 2022 | $61.9 | $62.0 | +0.2% |
| 2023 | $62.0 | $61.2 | -1.3% |
| 2024 | $61.2 | $78.5 | +28% |
| 2025 | $78.5 | $62.8 | -20% |
| 2026 YTD | $62.8 | $45.3 | -28% |
PBH has finished lower in three of the last six years. It's down 28% so far in 2026.